Skip to main content
Premium Trial:

Request an Annual Quote

Reagents Business Drives up GenMark's Q1 Revenues 185 Percent

NEW YORK (GenomeWeb News) – GenMark Diagnostics reported after the close of the market on Tuesday that revenues for the first quarter increased 185 percent year over year, led by reagents revenues.

For the period ended March 31, total revenues increased to $2.2 million from $758,000, as product revenues rose to $2.1 million from $693,000 while license and other revenues dropped to $39,000 from $65,000.

According to GenMark, the sharp revenue improvement resulted from an increase in the number of systems placed at customer sites, growth in test menus, and a "significant increase" in the number of tests sold.

Within product revenues, reagent revenues rose 213 percent to $1.9 million from $608,000, and instrument and other revenues spiked 60 percent to $240,000 from $150,000, the Carlsbad, Calif.-based firm said.

During the first quarter, it placed a net 22 analyzers — including eight sales — for a total installed base of 189 analyzers.

Its R&D expenses contracted 27 percent year over year to $1.9 million from $2.6 million. The decrease was due to a non-recurring costs incurred in Q1 2011 related to the move of GenMark's operations from Pasadena, Calif., and the US Food and Drug certification of the Carlsbad facility, as well as lower clinical trial expenses, Richard Slansky, the company's new CFO, said on a conference call after the release of its earnings results.

The firm's SG&A costs rose to $4.0 million from $3.3 million, a 21 percent uptick resulting from revenue, headcount growth, and other corporate expenses, GenMark said.

Its net loss for the quarter was $5.6 million, or $.28 per share, down from a net loss of $6.6 million, or $.56 per share, a year ago.

GenMark ended the quarter with $23.8 million in cash and cash equivalents.

The company continues to progress on the development of its diagnostics test pipeline as well as its next-generation e-Sensor sample-to-answer platform, company officials said. Discussing the platform, GenMark President and CEO Hany Massarany said during the conference call that the goal is to have a prototype instrument in the fourth quarter with a commercial launch slated for late 2013.

Recently, GenMark announced deals with PerkinElmer and Advanced Liquid Logic related to microfluidic technology. Today, Massarany said those deals "will provide us with maximum flexibility as we complete the development of our next-gen platform and its menu."

The initial focus of the new platform will be on multiplexed molecular testing followed by other areas of diagnostics including protein detection and point-of-care testing, he added.

Massarany also said that the firm is laying the groundwork to enter international markets, including obtaining ISO certifications and CE marking, though he noted that GenMark does not have "significant expectations" about revenues it may receive this year resulting from those plans.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.